Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$12.07 USD
+0.59 (5.14%)
Updated May 31, 2024 04:00 PM ET
After-Market: $12.09 +0.02 (0.17%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 181 - 190 ( 190 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
RPL554 is Winning the Clinical Beauty Contest in COPD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
We reiterate our OUTPERFORM rating and a 12-month price target of $25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L